Amp Volatility Score
Catalyst Info & Data Links
TITLE: ATI-450 for Cytokine Release Syndrom in COVID-19 Patients Phase 2 Readout
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
ATI-450 is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor in Phase 2 clinical development. This mechanism leads to the inhibition of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals. Key inflammatory cytokines driven by this mechanism include tumor necrosis factor α (TNFα) and interleukin-1α, -1β, -6 and -8 (IL1α, IL1β, IL6 and IL8). Aclaris is developing ATI-450 as a potential treatment for rheumatoid arthritis and other immuno-inflammatory diseases.
Updated by MV
#COVIDtherapeutic #COVIDtherapy #infectiousdisease #ACRS #ATI-450 #ATI450
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post